UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the U.S.

To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...